简介：这研究在跟随加速的transepithelial的keratoconus角膜评估了临床的结果角膜的骨胶原cross-linking(CXL)(AvedroKXL?系统，麻省沃尔瑟姆，美国)超过一年后续。光连贯断层摄影术(10月)测量的分界线的吝啬的深度是205.19???吳????????<

简介：AIM:Todeterminereallifeclinicaloutcomesinpoorlyresponsiveandtreatment-naveneovascularage-relatedmaculardegeneration(nvAMD)patientsusingbimonthlyfixeddosingafliberceptregimen.METHODS:Thiswasaretrospectivestudyof165eyeswithnvAMDstartedonafliberceptatSouthamptonEyeUnitbetweenJune2013andJune2014.Patientswereeitherswitchedfromprorenata(PRN)ranibizumab/bevacizumabduetopoorresponse(107eyes),ortreatment-nave(58eyes).Patientsinitiallyreceived3-monthlyintravitrealafliberceptinjectionsfollowedby2-monthlyfixeddoses.Clinicvisitswerescheduledatmonth0,4,10and12.Meanchangeinbest-correctedvisualacuity(BCVA)andcentralretinalthickness(CRT)frombaselinewereassessedusingtheWilcoxonsignedranktest.TheproportionofpatientsmaintainingBCVA(<15lettersloss)at12mowasalsoevaluated.RESULTS:MeanBCVAchangeatmonth12was+3.29and+4.67lettersintheswitchedandnaveafliberceptgroupsrespectively(P<0.01).BCVAwasmaintainedin95.3%ofswitchedand96.6%ofnavepatients.CRTatmonth12showedadecreaseof-6.16μmintheswitchedgroupand-35.36μminthenavegroup(P<0.01).Patientspreviouslytreatedwithranibizumab/bevacizumabhadonaveragereceived7.4ranibizumab/bevacizumabinjectionsover12.6mo,attending10clinicvisits.Thefixeddosingafliberceptregimenrequiredanaverageof7.1injections(navegroup),7.5injections(switchedgroup)and4clinicvisitsperyear.CONCLUSION:Fixedbimonthlyafliberceptiseffectiveinbothtreatment-naveandpoorlyresponsivenvAMDpatients.Adoptingafixeddosingregimencanreducepatientburdenwithoutcompromisingonoutcomes.

简介：

简介：AIM:Toevaluatetheefficacyandsafetyofacombinedtreatmentformyopicchoroidalneovascularization(CNV)usingphotodynamictherapy(PDT)andintravitrealbevacizumabandtocompareitwithintravitrealbevacizumabmonotherapy.METHODS:Thirty-foureyeswithangiographicevidenceofmyopicCNVwererandomlydividedintotwogroups:17weretreatedwithoneintravitrealbevacizumabinjection(1.25mg)andlow-fluence-ratePDTwithinsevendaysoftheinjection(GroupA).Theother17receivedmonotherapywithbevacizumabinjections(GroupB).Clinicalevidenceofcomplications,bestcorrectedvisualacuity(BCVA)andfluoresceinleakagewereevaluated.BCVAandopticalcoherencetomography(OCT)wereevaluatedmonthly.Thetimepointsfollow-upwasestablishedat6and12mo.AllpatientswereretreatedfollowingaPRNprotocol.RESULTS:Atotalof34eyesof34patients(26womenand8men)withameanageof62.35yearswereincluded.InGroupA(17eyes)themeanBCVAincreasedfrom0.55±0.13logMARbeforethetreatmentto0.40±0.09logMARatthe12mofollow-up(P<0.01).InGroupB(17eyes)themeanBCVAincreasedfrom0.60±0.11logMARbeforethetreatmentto0.55±0.12logMARatthe12mofollow-up(P<0.01).TherewasnostatisticallysignificantdifferencebetweenthetwogroupsintermsofLogMarvisualacuity.InGroupAthemeannumberofcombinedtreatmentswas1.8±0.11perpatient;inGroupBthemeannumberofintravitrealbevacizumabinjectionswas3.1±0.08perpatient.ThenumberoftreatmentswassignificantlyfewerinGroupA(P<0.01).Nolocalorsystemicsideeffectsoccurredamonganyofthepatientstreatedinthisstudy.CONCLUSION:Thecombinationofanti-angiogenicinjectionsandPDTappearstobeasafeandeffectiveoptionformyopicCNVtreatmentandallowsforasignificantreductionofintravitrealinjections.

简介：AIMTo在Descemet的家根据厚度评估视觉尖酸和endothelial房间密度剥去自动化endothelialkeratoplasty(DSAEK)在外科以后的年。

简介：